An analyst from Maxim has begun coverage of Akari Therapeutics (AKTX, Financial), assigning a Buy rating and setting a price target of $5. This suggests confidence in the company's future growth potential and may indicate a promising opportunity for investors considering this stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Akari Therapeutics PLC (AKTX, Financial) is $7.00 with a high estimate of $7.00 and a low estimate of $7.00. The average target implies an upside of 519.47% from the current price of $1.13. More detailed estimate data can be found on the Akari Therapeutics PLC (AKTX) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Akari Therapeutics PLC's (AKTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
